Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–any
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Body mass index within the range 18.5-29.9 (kg/m2)
Current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of \< 10 pack years.
Additional criteria for Cohorts 2 and 3 only (Asthmatic Patients):
Subjects with a documented history of mild to moderate asthma, with the exclusion of other significant pulmonary disease
Subjects with clinically stable asthma within the 4 weeks preceding the screening visit and with a screening pre-bronchodilator FEV1 greater than 60% and less than 90% predicted.
During the screening visit, subjects must demonstrate the presence of reversible airway disease, defined as an increase in FEV1 of \> or equal to 12.0% over baseline and an absolute change of \> or equal to 300 mL within 30 minutes following 400 mcg salbutamol.
You may not be if
Any clinically relevant abnormality
Subjects who have a screening haemoglobin values \< 11 g/dL
The subject has participated in a clinical study with a New Chemical Entity (NCE) within the past 112 days or a clinical study with any other drug during the previous 84 days
Subjects with known hypersensitivity to salmeterol or salbutamol or any ingredients in their preparations.
Clareo Health | GSK159802 In Healthy Male Subjects And Asthmatics
